clonoSEQ
Multiple Myeloma (Bone Marrow)
Key Facts
About Adaptive Biotechnologies
Adaptive Biotechnologies is translating the genetics of the adaptive immune system into clinical insights and novel therapies. Founded in 2009, the company has commercialized the clonoSEQ MRD assay and built a massive database of immune receptor sequences to fuel its drug discovery engine. Its strategic direction focuses on expanding its diagnostic portfolio and advancing its pipeline of TCR and antibody therapeutics through internal development and partnerships.
View full company profileAbout Adaptive Biotechnologies
Adaptive Biotechnologies is translating the genetics of the adaptive immune system into clinical insights and novel therapies. Founded in 2009, the company has commercialized the clonoSEQ MRD assay and built a massive database of immune receptor sequences to fuel its drug discovery engine. Its strategic direction focuses on expanding its diagnostic portfolio and advancing its pipeline of TCR and antibody therapeutics through internal development and partnerships.
View full company profileAbout Adaptive Biotechnologies
Adaptive Biotechnologies is translating the genetics of the adaptive immune system into clinical insights and novel therapies. Founded in 2009, the company has commercialized the clonoSEQ MRD assay and built a massive database of immune receptor sequences to fuel its drug discovery engine. Its strategic direction focuses on expanding its diagnostic portfolio and advancing its pipeline of TCR and antibody therapeutics through internal development and partnerships.
View full company profileAbout Adaptive Biotechnologies
Adaptive Biotechnologies is translating the genetics of the adaptive immune system into clinical insights and novel therapies. Founded in 2009, the company has commercialized the clonoSEQ MRD assay and built a massive database of immune receptor sequences to fuel its drug discovery engine. Its strategic direction focuses on expanding its diagnostic portfolio and advancing its pipeline of TCR and antibody therapeutics through internal development and partnerships.
View full company profileAbout Adaptive Biotechnologies
Adaptive Biotechnologies is translating the genetics of the adaptive immune system into clinical insights and novel therapies. Founded in 2009, the company has commercialized the clonoSEQ MRD assay and built a massive database of immune receptor sequences to fuel its drug discovery engine. Its strategic direction focuses on expanding its diagnostic portfolio and advancing its pipeline of TCR and antibody therapeutics through internal development and partnerships.
View full company profileAbout Adaptive Biotechnologies
Adaptive Biotechnologies is translating the genetics of the adaptive immune system into clinical insights and novel therapies. Founded in 2009, the company has commercialized the clonoSEQ MRD assay and built a massive database of immune receptor sequences to fuel its drug discovery engine. Its strategic direction focuses on expanding its diagnostic portfolio and advancing its pipeline of TCR and antibody therapeutics through internal development and partnerships.
View full company profileAbout Adaptive Biotechnologies
Adaptive Biotechnologies is translating the genetics of the adaptive immune system into clinical insights and novel therapies. Founded in 2009, the company has commercialized the clonoSEQ MRD assay and built a massive database of immune receptor sequences to fuel its drug discovery engine. Its strategic direction focuses on expanding its diagnostic portfolio and advancing its pipeline of TCR and antibody therapeutics through internal development and partnerships.
View full company profileAbout Adaptive Biotechnologies
Adaptive Biotechnologies is translating the genetics of the adaptive immune system into clinical insights and novel therapies. Founded in 2009, the company has commercialized the clonoSEQ MRD assay and built a massive database of immune receptor sequences to fuel its drug discovery engine. Its strategic direction focuses on expanding its diagnostic portfolio and advancing its pipeline of TCR and antibody therapeutics through internal development and partnerships.
View full company profileAbout Adaptive Biotechnologies
Adaptive Biotechnologies is translating the genetics of the adaptive immune system into clinical insights and novel therapies. Founded in 2009, the company has commercialized the clonoSEQ MRD assay and built a massive database of immune receptor sequences to fuel its drug discovery engine. Its strategic direction focuses on expanding its diagnostic portfolio and advancing its pipeline of TCR and antibody therapeutics through internal development and partnerships.
View full company profile